Trial Profile
The randomized, double-blind, placebo-controlled anddose escalation I phase study evaluating the tolerence, pharmacokenetics and efficacy of single dose andescalating dose to target dose every week of CJC-1134- PC in healthy subjects
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 28 Feb 2022
Price :
$35
*
At a glance
- Drugs Albenatide (Primary)
- Indications Solid tumours; Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Kaijiejian Biopharmaceutical
- 10 Feb 2016 New trial record